Considerations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 2—Ex vivo imaging: Added value and acquisition

Kurt G. Schilling*, Francesco Grussu, Andrada Ianus, Brian Hansen, Amy F. D. Howard, Rachel L. C. Barrett, Manisha Aggarwal, Stijn Michielse, Fatima Nasrallah, Warda Syeda, Nian Wang, Jelle Veraart, Alard Roebroeck, Andrew F. Bagdasarian, Cornelius Eichner, Farshid Sepehrband, Jan Zimmermann, Lucas Soustelle, Christien Bowman, Benjamin C. TendlerAndreea Hertanu, Ben Jeurissen, Marleen Verhoye, Lucio Frydman, Yohan van de Looij, David Hike, Jeff F. Dunn, Karla Miller, Bennett A. Landman, Noam Shemesh, Adam Anderson, Emilie Mckinnon, Shawna Farquharson, Flavio Dell'Acqua, Carlo Pierpaoli, Ivana Drobnjak, Alexander Leemans, Kevin D. Harkins, Maxime Descoteaux, Duan Xu, Hao Huang, Mathieu D. Santin, Samuel C. Grant, Andre Obenaus, Gene S. Kim, Dan Wu, Denis Le Bihan, Stephen J. Blackband, Luisa Ciobanu, Els Fieremans, Et al.

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The value of preclinical diffusion MRI (dMRI) is substantial. While dMRI enables in vivo non-invasive characterization of tissue, ex vivo dMRI is increasingly being used to probe tissue microstructure and brain connectivity. Ex vivo dMRI has several experimental advantages including higher SNR and spatial resolution compared to in vivo studies, and enabling more advanced diffusion contrasts for improved microstructure and connectivity characterization. Another major advantage of ex vivo dMRI is the direct comparison with histological data, as a crucial methodological validation. However, there are a number of considerations that must be made when performing ex vivo experiments. The steps from tissue preparation, image acquisition and processing, and interpretation of results are complex, with many decisions that not only differ dramatically from in vivo imaging of small animals, but ultimately affect what questions can be answered using the data. This work represents "Part 2" of a three-part series of recommendations and considerations for preclinical dMRI. We describe best practices for dMRI of ex vivo tissue, with a focus on the value that ex vivo imaging adds to the field of dMRI and considerations in ex vivo image acquisition. We first give general considerations and foundational knowledge that must be considered when designing experiments. We briefly describe differences in specimens and models and discuss why some may be more or less appropriate for different studies. We then give guidelines for ex vivo protocols, including tissue fixation, sample preparation, and MR scanning. In each section, we attempt to provide guidelines and recommendations, but also highlight areas for which no guidelines exist (and why), and where future work should lie. An overarching goal herein is to enhance the rigor and reproducibility of ex vivo dMRI acquisitions and analyses, and thereby advance biomedical knowledge.
Original languageEnglish
Pages (from-to)2535-2560
Number of pages26
JournalMagnetic Resonance in Medicine
Volume93
Issue number6
Early online date4 Mar 2025
DOIs
Publication statusE-pub ahead of print - 4 Mar 2025

Keywords

  • acquisition
  • best practices
  • diffusion MRI
  • diffusion tensor
  • ex vivo
  • microstructure
  • open science
  • preclinical
  • processing
  • tractography
  • MAGNETIC-RESONANCE MICROSCOPY
  • POSTMORTEM HUMAN BRAINS
  • WAXHOLM SPACE ATLAS
  • WATER DIFFUSION
  • AXON DIAMETER
  • WHITE-MATTER
  • MOUSE-BRAIN
  • IN-VIVO
  • TENSOR MICROSCOPY
  • T-2 RELAXATION

Fingerprint

Dive into the research topics of 'Considerations and recommendations from the ISMRM diffusion study group for preclinical diffusion MRI: Part 2—Ex vivo imaging: Added value and acquisition'. Together they form a unique fingerprint.

Cite this